STOCK TITAN

Major Investment Fund Bets Big on Biotech Processa Pharmaceuticals with 2.6M Share Position

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

A Schedule 13G filing reveals that CVI Investments and Heights Capital Management have acquired a significant 9.9% stake in Processa Pharmaceuticals, holding 2,663,078 shares. The position consists of 2,200,000 common shares and additional warrants.

Key details of the investment:

  • CVI Investments (Cayman Islands) and Heights Capital Management (Delaware) share voting and dispositive power over all shares
  • Heights Capital Management serves as investment manager to CVI Investments
  • Ownership includes pre-funded warrants and other warrants with a 9.99% exercise limitation
  • Total outstanding shares reported as 26,194,356 as of June 18, 2025

The filing confirms the securities were not acquired to influence control of Processa Pharmaceuticals. The transaction appears to be a passive investment, with both entities filing jointly through their authorized representative Sarah Travis on June 24, 2025.

Positive

  • CVI Investments, Inc. and Heights Capital Management have acquired a significant 9.9% stake in Processa Pharmaceuticals through a combination of shares (2,200,000) and warrants
  • The investment represents a substantial institutional commitment, with the stake being large enough to require 13G disclosure

Negative

  • The ownership includes pre-funded warrants and other warrants that are subject to a 9.99% ownership limitation, indicating potential future dilution if exercised





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


SCHEDULE 13G



CVI Investments, Inc.
Signature:/s/ Sarah Travis
Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc.
Date:06/24/2025
Heights Capital Management, Inc.
Signature:/s/ Sarah Travis
Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary
Date:06/24/2025

Comments accompanying signature: Heights Capital Management, Inc. serves as authorized agent of CVI Investments, Inc. pursuant to a Limited Power of Attorney, a copy of which is attached as Exhibit I hereto.
Exhibit Information

EXHIBIT INDEX EXHIBIT DESCRIPTION ________ ________ I Limited Power of Attorney II Joint Filing Agreement

FAQ

What percentage of PCSA stock does CVI Investments own as of June 2025?

According to the Schedule 13G filing, CVI Investments, Inc. beneficially owns 9.9% of Processa Pharmaceuticals (PCSA) common stock, representing 2,663,078 shares as of June 17, 2025.

How many PCSA shares does CVI Investments control through voting power?

CVI Investments has shared voting power over 2,663,078 shares of PCSA stock, with no sole voting power. The voting power is shared with Heights Capital Management, Inc., which serves as CVI Investments' investment manager.

What is the breakdown of PCSA shares held by CVI Investments?

CVI Investments holds 2,200,000 direct shares of PCSA, plus additional shares issuable through pre-funded warrants and other warrants. The warrants are subject to a 9.99% beneficial ownership limitation based on the total outstanding shares.

Who manages CVI Investments' PCSA holdings?

Heights Capital Management, Inc., based in San Francisco, California, serves as the investment manager to CVI Investments, Inc. and exercises voting and dispositive power over the PCSA shares beneficially owned by CVI Investments.

How many total outstanding shares does PCSA have as of June 2025?

According to the Company's Prospectus (Registration No. 333-287997) referenced in the filing, PCSA had 26,194,356 shares outstanding as of June 18, 2025, excluding shares underlying the warrants.
Processa Pharmaceuticals Inc

NASDAQ:PCSA

View PCSA Stock Overview

PCSA Rankings

PCSA Latest News

PCSA Latest SEC Filings

PCSA Stock Data

6.20M
1.93M
Biotechnology
Pharmaceutical Preparations
Link
United States
VERO BEACH